ACAD insider transaction filings
ACADIA PHARMACEUTICALS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-07. Screen ACAD transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 3 filings by 3 insiders — 48,120 shares, $1,317,817 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 16,508 shares @ $26.13 ($431,354) by Thompson Elizabeth H.Z., filed 2026-07-31.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | 1 | — | 3 legs · 20,141 sh · $587,242 | 4 |
| Thompson Elizabeth H.Z. — EVP, Head of Research & Dev | 1 | — | 2 legs · 16,558 sh · $432,663 | 2 |
| Kihara James — PRINCIPAL ACCOUNTING OFFICER | 1 | — | 1 leg · 11,421 sh · $297,912 | — |
Recent Form 4 filings — ACADIA PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 5,849 @ $17.84 · Sale (S): 5,849 @ $29.00 · Option exercise (M): 14,292 @ $17.84 · Sale (S): 5,000 @ $29 · Sale (S): 9,292 @ $29.34 · Option exercise (M): 5,849 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-31 | 4 | Thompson Elizabeth H.Z. — EVP, Head of Research & Dev | Option exercise (M): 32,272 · Sale (S): 16,508 @ $26.13 · Sale (S): 50 @ $26.17 · Option exercise (M): 32,272 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Sale (S): 11,421 @ $26.08 | EDGAR |
| 2026-06-02 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 18,622 @ $0 · Grant/award (A): 18,622 @ $0 · Grant/award (A): 32,008 (derivative) @ $0 · Grant/award (A): 32,008 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Ndu Adora — Director | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | GAROFALO ELIZABETH A. — Director | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Poole Jonathan — Director | Option exercise (M): 2,010 · Option exercise (M): 2,010 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Daly James M — Director | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Brege Laura — Director | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | HARRIGAN EDMUND — Director | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Sale (S): 5,401 @ $21.18 | EDGAR |
| 2026-05-05 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 6,815 · Sale (S): 3,506 @ $21.79 · Option exercise (M): 6,815 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 2,596 · Sale (S): 1,332 @ $21.79 · Option exercise (M): 2,596 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 5,276 · Sale (S): 2,709 @ $22.20 · Option exercise (M): 5,276 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 2,010 · Sale (S): 1,030 @ $22.20 · Option exercise (M): 2,010 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 8,138 · Sale (S): 4,177 @ $21.47 · Option exercise (M): 6,178 · Sale (S): 3,171 @ $21.65 · Sale (S): 37 @ $21.72 · Option exercise (M): 8,138 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-26 | 4 | Thompson Elizabeth H.Z. — EVP, Head of Research & Dev | Option exercise (M): 6,715 · Sale (S): 3,435 @ $21.47 · Option exercise (M): 6,715 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Owen Adams Catherine — Chief Executive Officer, Director | Option exercise (M): 23,509 @ $0 · Sale (S): 11,641 @ $21.47 · Option exercise (M): 23,509 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 1,627 · Sale (S): 833 @ $21.47 · Option exercise (M): 2,142 · Sale (S): 1,097 @ $21.65 · Sale (S): 12 @ $21.73 · Option exercise (M): 1,627 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-26 | 4 | Rhodes Jennifer J — EVP, CHIEF LEGAL OFFICER, SEC | Option exercise (M): 7,515 @ $0 · Sale (S): 3,844 @ $21.47 · Option exercise (M): 7,515 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Poole Jonathan — Director | Grant/award (A): 7,482 (derivative) @ $0 · Grant/award (A): 3,565 (derivative) @ $0 · Grant/award (A): 4,218 (derivative) @ $0 · Grant/award (A): 2,010 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Garner Thomas — EVP, Chief Commercial Officer | Grant/award (A): 97,947 (derivative) @ $0 · Grant/award (A): 28,493 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 90,691 (derivative) @ $0 · Grant/award (A): 26,382 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Thompson Elizabeth H.Z. — EVP, Head of Research & Dev | Grant/award (A): 101,574 (derivative) @ $0 · Grant/award (A): 29,548 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Owen Adams Catherine — Chief Executive Officer, Director | Grant/award (A): 263,005 (derivative) @ $0 · Grant/award (A): 76,509 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Grant/award (A): 21,766 (derivative) @ $0 · Grant/award (A): 6,332 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Rhodes Jennifer J — EVP, CHIEF LEGAL OFFICER, SEC | Grant/award (A): 90,691 (derivative) @ $0 · Grant/award (A): 26,382 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Rhodes Jennifer J — EVP, CHIEF LEGAL OFFICER, SEC | Option exercise (M): 12,944 @ $0 · Sale (S): 6,950 @ $23.38 · Option exercise (M): 12,944 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 9,913 · Option exercise (M): 9,913 · Sale (S): 10,262 @ $23.69 · Option exercise (M): 9,913 (derivative) @ $0 · Option exercise (M): 9,913 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 3,966 · Option exercise (M): 3,966 · Sale (S): 4,084 @ $23.69 · Option exercise (M): 3,966 (derivative) @ $0 · Option exercise (M): 3,966 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Daly James M — Director | Sale (S): 30,000 @ $22.37 | EDGAR |
| 2025-09-16 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 6,815 @ $0 · Sale (S): 3,498 @ $23.65 | EDGAR |
| 2025-09-03 | 4 | GAROFALO ELIZABETH A. — Director | Sale (S): 1,600 @ $25.98 | EDGAR |
| 2025-08-19 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 22,000 @ $25.18 | EDGAR |
| 2025-06-05 | 4 | Brege Laura — Director | Sale (S): 14,446 @ $21.78 | EDGAR |
| 2025-06-02 | 4 | SOLAND DANIEL B — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Ndu Adora — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | HARRIGAN EDMUND — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | GAROFALO ELIZABETH A. — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Daly James M — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Brege Laura — Director | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 16,214 @ $0 · Grant/award (A): 16,214 @ $0 · Grant/award (A): 27,586 (derivative) @ $0 · Grant/award (A): 27,586 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Sale (S): 2,000 @ $25 · Sale (S): 2,000 @ $20 | EDGAR |
| 2025-05-19 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 2,000 @ $25 | EDGAR |
| 2025-05-02 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 2,596 · Sale (S): 1,327 @ $14.60 · Option exercise (M): 2,596 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 6,815 · Sale (S): 3,498 @ $14.60 · Option exercise (M): 6,815 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER | Option exercise (M): 5,275 · Sale (S): 2,708 @ $14.82 · Option exercise (M): 5,275 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | Kihara James — PRINCIPAL ACCOUNTING OFFICER | Option exercise (M): 2,010 · Sale (S): 1,028 @ $14.82 · Option exercise (M): 2,010 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Thompson Elizabeth H.Z. — EVP, Head of Research & Dev | Grant/award (A): 91,395 (derivative) @ $0 · Grant/award (A): 26,861 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Owen Adams Catherine — Chief Executive Officer, Director | Grant/award (A): 319,976 (derivative) @ $0 · Grant/award (A): 94,039 (derivative) @ $0 | EDGAR |
Recent 8-K events — ACADIA PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACAD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →